Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure
Circulation. 2024 Mar 12;149(11):839-842. doi: 10.1161/CIRCULATIONAHA.123.068089. Epub 2024 Mar 11.NO ABSTRACTPMID:38466791 | DOI:10.1161/CIRCULATIONAHA.123.068089 (Source: Circulation)
Source: Circulation - March 11, 2024 Category: Cardiology Authors: John G F Cleland Source Type: research
Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure
Circulation. 2024 Mar 12;149(11):839-842. doi: 10.1161/CIRCULATIONAHA.123.068089. Epub 2024 Mar 11.NO ABSTRACTPMID:38466791 | DOI:10.1161/CIRCULATIONAHA.123.068089 (Source: Circulation)
Source: Circulation - March 11, 2024 Category: Cardiology Authors: John G F Cleland Source Type: research
Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice
(Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy)
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - March 11, 2024 Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity Source Type: research
Molecules, Vol. 29, Pages 1236: The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications
In conclusion, our results showed that the co-administration of grapefruit with empagliflozin should be cautiously monitored and avoided, in which grapefruit elevates the plasma level of empagliflozin. This may be attributed to the inhibition of the uridine enzyme in the grapefruit by hesperidin, naringin, and flavonoid. (Source: Molecules)
Source: Molecules - March 11, 2024 Category: Chemistry Authors: Wael Abu Dayyih Zainab Zakaraya Mohammad Hailat Nafe M. Al-Tawarah Sahem Alkharabsheh Haya Khalid Nadher Zeyad Hailat Samia M. Alarman Anas Khaleel Riad Awad Tags: Article Source Type: research
Early SGLT2 inhibitor use is associated with improved left atrial strain following acute coronary syndrome
CONCLUSION: In patients with ACS and T2D, addition of empagliflozin to standard ACS therapy prior to discharge is associated with improved LA function.PMID:38456717 | DOI:10.1080/00015385.2024.2324221 (Source: Acta Cardiologica)
Source: Acta Cardiologica - March 8, 2024 Category: Cardiology Authors: Amro Sehly Albert He Abdul Rahman Ihdayhid Christine Grey Scott O'Connor Gillian Green Matthew Erickson James M Rankin P Gerry Fegan Bu B Yeap Girish Dwivedi Nick S R Lan Source Type: research
Adherence to newer second ‐line oral antidiabetic drugs among people with type 2 diabetes—A systematic review
The adherence to newer second-line oral antidiabetic drugs among people with type 2 diabetes was investigated in this study. A systematic literature search was performed in six databases. A total of 14948 records was retrieved from the databases of which 7 articles were included. The reported medication possession ratio (MPR) and treatment discontinuation was extracted from the articles, and these findings were visualised in figures and summarized in a narrative synthesis. The findings indicate that the adherence to the newer second-line OADs may be better than that of older OADs, but a study directly comparing older and n...
Source: Pharmacology Research and Perspectives - March 7, 2024 Category: Drugs & Pharmacology Authors: Nynne Sophie Holdt ‐Caspersen,
Claus Dethlefsen,
Peter Vestergaard,
Ole Hejlesen,
Stine Hangaard,
Morten Hasselstrøm Jensen Tags: REVIEW Source Type: research
Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial
ConclusionEmpagliflozin can have cardioprotective benefits in subjects without HF. Further studies are required to determine the effect of Empagliflozin in non-HF patients.Trial registrationThe original EMPA-CARD study has been registered in Iranian Registry of Clinical Trials.www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective. (Source: Journal of Diabetes and Metabolic Disorders)
Source: Journal of Diabetes and Metabolic Disorders - March 7, 2024 Category: Endocrinology Source Type: research
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR ‐Preserved analysis
ConclusionIn EMPEROR-Preserved, LRTI was frequent and associated with a poor prognosis. Empagliflozin was associated with a reduced risk of LRTI compared to placebo. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 5, 2024 Category: Cardiology Authors: Jo ão Pedro Ferreira,
Faiez Zannad,
Milton Packer,
Gerasimos Filippatos,
Stuart J. Pocock,
Francisco Vasques‐Nóvoa,
Michael Böhm,
Javed Butler,
Stefan Anker Tags: Research Article Source Type: research
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme
ConclusionAcross the range of EF in patients with chronic HF enrolled in the EMPEROR trials, the majority of whom did not have clinical evidence of congestion, CA-125 concentrations were not significantly associated with congestive signs or symptoms. CA-125 concentrations may predict HF hospitalization/CV death in patients with HFrEF, but not those with HFpEF.Clinical Trial Registration: EMPEROR-Reduced (NCT03057977), EMPEROR-Preserved (NCT03057951). (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 5, 2024 Category: Cardiology Authors: Jo ão Pedro Ferreira,
Milton Packer,
Naveed Sattar,
Javed Butler,
Stuart J. Pocock,
Stefan D. Anker,
Sandra González Maldonado,
Marina Panova‐Noeva,
Mikhail Sumin,
Serge Masson,
Faiez Zannad,
James L. Januzzi Tags: Research Article Source Type: research
Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes
While the cardiovascular (CV) benefits with sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with diabetes mellitus (DM) are well known, their effects in patients without DM continue to be explored. We provide a meta-analysis of the available evidence. Online databases were searched for randomized controlled trials (RCTs) comparing SGLT2i to placebo/control in patients without DM. The endpoints of interest were composite CV death/hospitalization for heart failure (HF) with individual components, all cause death, major adverse CV events (MACE) and serious adverse events. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 29, 2024 Category: Cardiology Authors: Sahib Singh, Aakash Garg, Udaya S Tantry, Kevin Bliden, Paul A Gurbel, Martha Gulati Source Type: research
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities. Currently, there are no therapies targeting this important clinical problem. Sodium-glucose cotransporter 2 inhibitors (SGLT2... (Source: Cardiovascular Diabetology)
Source: Cardiovascular Diabetology - February 29, 2024 Category: Cardiology Authors: Ellen Vercalsteren, Dimitra Karampatsi, Carolina Buizza, Thomas Nystr öm, Thomas Klein, Gesine Paul, Cesare Patrone and Vladimer Darsalia Tags: Research Source Type: research
A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials
CONCLUSIONS: Empagliflozin is the first treatment with established efficacy and cost-effectiveness for HF patients across EF from the perspective of healthcare payers in Spain. Empagliflozin also proved to be cost-effective for all subgroups of patients included in the analysis.PMID:38416135 | DOI:10.1080/14779072.2024.2324027 (Source: Expert Review of Cardiovascular Therapy)
Source: Expert Review of Cardiovascular Therapy - February 28, 2024 Category: Cardiology Authors: Xavier Garc ía-Moll Francesco Croci Alexandra Sol é Elisabeth S Hartgers-Gubbels Miguel A Calleja-Hern ández Source Type: research
